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Abstract 
Daclatasvir, a HCV NS5A inhibitor, is a new direct-acting antiviral drug for chronic hepatitis C (CHC). This study aimed 
to evaluate the efficacy and safety of daclatasvir combined with peginterferon-α (pegIFN-α) and ribavirin (RBV) for the 
treatment of CHC. The databases of PUBMED, EMBASE, COCHRANE, WANFANG, and CNKI were retrieved to identify 
eligible studies. Pooled risk ratio (RR) and 95 % confidence interval (CI) were calculated using random or fixed models. 
A total of six RCTs including 1100 adult patients with CHC met the inclusion criteria and the patients were infected 
with HCV genotype 1–4, with the genotype 1 infection accounting for 73.1 %. Meta-analysis showed daclatasvir-
based combination therapy yielded a significantly higher probability of achieving the overall RVR (46.43 vs. 18.97 %) 
with pooled RR of 3.77 (95 % CI 1.95–7.28, p < 0.0001) and a slightly higher probability of achieving the overall SVR24 
(65.08 vs. 47.77 %) with pooled RR of 1.41 (95 % CI 1.18–1.68, p < 0.0001), and did not show increased adverse events 
compared with the pegIFN-α/RBV regimen (control group). Subgroup analysis showed the rate of RVR and SVR24 in 
high-dose daclatasvir (60 mg/day) group were slightly higher than the overall results; the rate of RVR in low-dose 
daclatasvir (10 mg/day) group was also higher than the control group, but its SVR24 rate was similar between the two 
groups. Daclatasvir combined with pegIFN-α/RBV is effective and safe in treating adult patients with CHC, especially 
HCV genotype 1 infection, and daclatasvir (60 mg/day) is a better choice as compared with daclatasvir (10 mg/day).
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Background
Chronic hepatitis C virus (HCV) infection is common 
worldwide, affecting approximately 185 million peo-
ple globally, and is the cause of 704,000 deaths annually 
(World Health Organization 2016; Gower et  al. 2014; 
Chen and Ma 2014). About 75–85 % of all patients con-
tracting HCV will progress to chronic infection, with 
15–25  % of patients spontaneously clearing the infec-
tion (Centers for Disease Control and Prevention 2014). 
The progression between various stages of fibrosis can 
take decades, and often patients are asymptomatic until 
end-stage disease. Approximately one-third of patients 
with chronic HCV infection will develop cirrhosis or 
hepatocellular carcinoma (World Health Organization 
2016). So more and more attentions are paid to the early 
detection and treatment of chronic hepatitis C (CHC). 
The goal of treatment of CHC is to reduce associated 
morbidity and mortality and to improve health-related 
quality of life (AASLD/IDSA/IAS–USA 2014; American 
Association for the Study of the Liver 2016). Achieve-
ment of sustained virological response (SVR) is a sur-
rogate endpoint for these goals (Ghany et  al. 2009a, b; 
European Association for the Study of the Liver 2014a, b). 
Pegylated interferon-α (pegIFN-α) in combination with 
ribavirin (RBV) has always been the current standard 
of care for CHC, which result in remarkable biochemi-
cal and histological improvements in the liver (Chen and 
Li 2015; European Association for the Study of the Liver 
2014a, b). However, patients infected with HCV geno-
type 1 have experienced a poor response to this therapy 
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as observed by SVR rates of only 40–50 % (Chinese Soci-
ety of Hepatology et al. 2015).
In recent years, the direct antiviral agents (DAA) have 
gradually emerged, which include the nonstructural pro-
tein 3/4A (NS3/4A) protease inhibitor, the NS5A inhibi-
tor, the NS5B polymerase inhibitor, the NS4B protease 
inhibitor, and the NS3 protease inhibitor, etc (Wan et al. 
2014). The emergence of these drugs has brought new 
choice for the treatment. Daclatasvir is a first-in-class, 
potent, and highly selective NS5A replication complex 
inhibitor with broad genotypic coverage (genotypes 1–5) 
and a pharmacokinetic profile supportive of once-daily 
dosing (Degasperi et  al. 2015; Manolakopoulos et  al. 
2016; Keating 2016). Nettles et al. (2011) conducted the 
first randomized controlled trial (RCT), showing that 
daclatasvir in combination with pegIFN-α/RBV achieved 
satisfactory therapeutic effects. Subsequently, other stud-
ies with different design, location, and population further 
examined the efficacy of daclatasvir in the treatment of 
CHC. Here, we combined all published RCTs on this 
issue to quantitatively assess the efficacy and safety of 




A systematic search of PUBMED, EMBASE, 
COCHRANE, WANFANG, and CNKI (Chinese data-
base) was performed with no year restrictions. The 
search strategy included the following terms: ‘HCV’ 
(e.g. ‘hepatitis C’, ‘hepatitis C virus’, ‘HCV infection’); 
‘daclatasvir’ (e.g. ‘BMS-790052’); ‘RCT’ (e.g. ‘randomized 
controlled trial’). We carried out a second retrieval for 
the references of review.
Inclusion and exclusion criteria
Trials were considered for inclusion if they met the fol-
lowing four criteria. (a) The research type was RCT 
design. (b) This study was conducted in patients aged 
18–70  years who had chronic HCV infection over 
6  months with positive anti-HCV. Additional inclusion 
criteria included HCV-RNA  ≥  105  IU/ml. Meanwhile, 
serum urea nitrogen, creatinine and prothrombin activity 
were at normal levels. (c) Patients in experimental group 
were treated with daclatasvir in combination with peg-
IFN/RBV; while patients in control group were treated 
with placebo in combination with peg-IFN/RBV. (d) The 
Jadad score of RCTs should not be less than three points.
Trials were excluded if: (a) the study belonged to non-
randomized controlled trial (NRCT) or the Jadad score of 
RCTs was less than three points; (b) the study didn’t pro-
vide the outcome or the measurement; (c) the study was 
literature review or repeated other reports (Fig. 1).
Data extraction
Data extracted from each study included published infor-
mation (including the first author and published time); 
subjects (including the number of patients, gender, age, 
HCV-RNA content and viral genotype); treatment proto-
cols (including the drugs used in experimental group and 
control group, dosage regimen, course of the treatment, 
efficient individual quantity).
Quality assessment
We conducted a risk of bias assessment based on Jadad 
scores (Jadad et  al. 1996): (a) method of randomiza-
tion was mentioned; (b) method of randomization was 
appropriate; (c) the trial was double-blind; (d) method of 
blinding was identical placebo; (e) there was a descrip-
tion of withdraws and drop outs. If the study complied 
with any of the above description, it would get one point. 
The study with total score above 3 was divided into high-
quality research.
Statistical analysis
Statistical heterogeneity between studies was exam-
ined using the I2 value. I2 ranges of 25–<50, 50–<75 and 
≥75 % were considered to represent low, moderate, and 
high heterogeneity, respectively. If heterogeneity is low, 
we choose fixed-effects model, and if heterogeneity is 
moderate or high, we choose random-effects model (Tian 
et  al. 2013). Sensitive analysis was performed to exam-
ine the reliability of the results by omitting one study 
each time and recalculating the pooled RR. Publication 
bias was evaluated by visual inspection of Begg’s funnel 
plot and tested by the Begg’s test (significant at p < 0.1). 
In addition, the trim-and-fill method was used to adjust 
the pooled RR and 95 % CI if observed publication bias 
existed. All statistical analyses were completed using 
Stata statistical software version 12.0.
Results
Study characteristics
A total of 147 potentially relevant studies were identified 
through the electronic search. Through a review of titles 
and abstracts, 12 articles were chosen for full review. Six 
studies retrieved for further review were excluded. The 
remaining six studies met all criteria and were included 
in this meta-analysis. Baseline characteristics of included 
studies were presented in Table 1. Among these papers, 
there were 926 cases treated with daclatasvir in com-
bination with peg-IFN-α/RBV (daclatasvir group) and 
174 cases treated with peg-IFN-α/RBV (control group) 
and they were infected with HCV genotype 1–4 infec-
tion with the genotype 1 infection accounting for 73.1 %, 
published from 2012 to 2015. The sample sizes of these 
studies ranged from 42 to 419. Median age of the patients 
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ranged 50–57 years. The percentage of men in each treat-
ment arm ranged 22.0–75.0 %. The quality assessment of 
all RCTs were greater than or equal to 4, which indicated 
that all included articles were high quality (Table 2).
Overall analysis
Rapid virological response (RVR)
RVR was defined as an undetectable HCV-RNA level 
at 4  weeks after treatment initiation. A total of the six 
studies (Hézode et  al. 2015; Dore et  al. 2015; Suzuki 
et al. 2014; Izumi et al. 2014; Pol et al. 2012; Ratziu et al. 
2012) were included in this combined analysis. The test 
for the heterogeneity among the studies showed statis-
tical significance (I2  =  54.5  %), so the random-effects 
model was used. Meta-analysis results suggested that the 
overall RVR rate was significantly higher in daclatasvir 
group (46.43 %) as compared with that in control group 
(18.97  %) (RR  =  3.77, 95  % CI 1.95–7.28, p  <  0.0001, 
Fig.  2). Sensitive analysis showed that no individual 
studies could change the pooled results. Publication 
Fig. 1 Search strategy and flow of information relative to the meta-analysis
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bias did not exist (p = 0.851) when the Begger test was 
performed.
Sustained virological response at post‑treatment week 24 
(SVR24)
SVR24, defined as an undetectable viral load at the end of 
treatment and 24 weeks after the end of treatment, his-
torically has been regarded as a virologic cure. A total 
of the five studies (Hézode et al. 2015; Dore et al. 2015; 
Suzuki et al. 2014; Izumi et al. 2014; Pol et al. 2012) were 
included in this combined analysis. The test for the heter-
ogeneity showed that there was no statistical significance 
(I2 = 47.3 %), so the fixed-effects model was used. Meta-
analysis results revealed that the overall SVR24 rate was 
significantly higher in daclatasvir group (65.08 %) as com-
pared with that in control group (47.77  %) (RR =  1.41, 
95  % CI 1.18–1.68, p  <  0.0001, Fig.  3). Sensitive analy-
sis showed that no individual studies could change the 
pooled results. Publication bias did not exist (p = 0.624) 
when the Begger test was performed.
Relapse was defined as detectable HCV-RNA during 
24 week follow-up after undetectable HCV-RNA at end 
of treatment. A total of the five studies (Hézode et  al. 
2015; Dore et  al. 2015; Suzuki et  al. 2014; Izumi et  al. 
Table 2 Jadad score of clinical trials
Trial Randomization Double-blinding Withdraw and drop out Jadad score
Hézode et al. (2015) Method of randomization was  
mentioned and it was appropriate (2)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
5
Dore et al. (2015) Method of randomization was  
mentioned and it was appropriate (2)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
5
Suzuki et al. (2014) Method of randomization was  
mentioned and it was appropriate (2)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
5
Izumi et al. (2014) Method of randomization was  
mentioned and it was appropriate (2)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
5
Pol et al. (2012) Method of randomization was  
mentioned but not described (1)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
4
Ratziu et al. (2012) Method of randomization was  
mentioned but not described (1)
Method of blinding was 
identical placebo (2)
There was a description of  
withdraws and drop outs (1)
4
Fig. 2 Forest plot of RVR rate of DCV + P/R and PBO + P/R for CHC
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2014; Pol et  al. 2012) were included in this combined 
analysis. The test for the heterogeneity showed that there 
was no statistical significance (I2 = 43.9 %), so the fixed-
effects model was used. Meta-analysis results revealed 
that there were no significant differences between the 
two groups in the relapse rate (p =  0.40  >  0.05, Fig.  4). 
Sensitive analysis showed that no individual studies could 
change the pooled results. Publication bias did not exist 
(p = 0.624) when the Begger test was performed.
Treatment discontinuation due to an adverse event (TDAE)
TDAE was defined as subjects who stopped all study 
drugs due to an adverse event. A total of the five studies 
(Hézode et al. 2015; Dore et al. 2015; Suzuki et al. 2014; 
Fig. 3 Forest plot of SVR rate of DCV + P/R and PBO + P/R for CHC
Fig. 4 Forest plot of relapse rate of DCV + P/R and PBO + P/R for CHC
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Izumi et  al. 2014; Pol et  al. 2012) were included in this 
combined analysis. The test for the heterogeneity showed 
that there was no statistical significance (I2 = 0 %), so the 
fixed-effects model was used. Meta-analysis results indi-
cated that there were no significant differences between 
the two groups in the TDAE rate (p = 0.42 > 0.05, Fig. 5). 
Sensitive analysis showed that no individual studies could 
change the pooled results. Publication bias did not exist 
(p = 0.624) when the Begger test was performed.
Subgroup analysis
Effect of high‑dose (60 mg/day) use of daclatasvir on CHC
The RVR rate of daclatasvir (60 mg/day) It was defined 
as the rate of patients who had a HCV viral load below the 
limit of quantitation or detection at week 4 of treatment 
with daclatasvir (60 mg/day). A total of six studies (Hézode 
et al. 2015; Dore et al. 2015; Suzuki et al. 2014; Izumi et al. 
2014; Pol et al. 2012; Ratziu et al. 2012) were included in 
the subgroup. The test for the heterogeneity among the 
studies showed statistical significance (I2  =  52.2  %), so 
the random-effects model was used. Combined analy-
sis suggested that the RVR rate was significantly higher 
in daclatasvir (60 mg/day) group (49.90 %) as compared 
with that in control group (13.97 %) (RR = 3.76, 95 % CI 
1.97–7.16, p < 0.00001, Fig. 6). Sensitive analysis showed 
that no individual studies could change the pooled results. 
Publication bias did not exist (p = 0.851) when the Begger 
test was performed.
The SVR24 rate of daclatasvir (60 mg/day) It was defined 
as the rate of patients who had a negative HCV RNA 
test 24 weeks after the end of treatment with daclatasvir 
(60  mg/day). A total of five studies (Hézode et  al. 2015; 
Dore et al. 2015; Suzuki et al. 2014; Izumi et al. 2014; Pol 
et  al. 2012) were included in the subgroup. The test for 
heterogeneity showed that there was no statistical sig-
nificance (I2  =  40.6  %), so the fixed-effects model was 
used. Combined analysis revealed that the SVR24 rate 
was significantly higher in daclatasvir (60 mg/day) group 
(68.95 %) as compared with that in control group (47.77 %) 
(RR = 1.44, 95 % CI 1.21–1.71, p < 0.0001, Fig. 7). Sen-
sitive analysis showed that no individual studies could 
change the pooled results. Publication bias did not exist 
(p = 0.327) when the Begger test was performed.
Effect of low‑dose (10 mg/day) use of daclatasvir on CHC
The RVR rate of daclatasvir (10 mg/day) It was defined 
as the rate of patients who had a HCV viral load below 
the limit of quantitation or detection at week 4 of treat-
ment with daclatasvir (10 mg/day). A total of three stud-
ies (Suzuki et al. 2014; Izumi et al. 2014; Pol et al. 2012) 
were included in the subgroup. The test for heterogeneity 
showed that there was no statistical significance (I2 = 0 %), 
so the fixed-effects model was used. Combined analy-
sis suggested that the RVR rate was significantly higher 
in daclatasvir (10 mg/day) group (74.47 %) as compared 
with that in control group (7.14 %) (RR = 8.79, 95 % CI 
Fig. 5 Forest plot of TDAE rate of DCV + P/R and PBO + P/R for CHC
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2.67–28.95, p < 0.0001, Fig. 8). Sensitive analysis showed 
that no individual studies could change the pooled results. 
Publication bias did not exist (p = 0.602) when the Begger 
test was performed.
The SVR24 rate of daclatasvir (10 mg/day) It was defined 
as the rate of patients who had a negative HCV RNA test 
24 weeks after the end of treatment with daclatasvir (10 mg/
day). A total of three studies (Suzuki et  al. 2014; Izumi 
et al. 2014; Pol et al. 2012) were included in the subgroup. 
The test for the heterogeneity among the studies showed 
statistical significance (I2 = 71.5 %), so the random-effects 
model was used. Combined analysis revealed that there 
were no significant differences between the two groups in 
Fig. 6 Forest plot of RVR rate of DCV (60 mg/day) + P/R and PBO + P/R for CHC
Fig. 7 Forest plot of SVR rate of DCV (60 mg/day) + P/R and PBO + P/R for CHC
Page 10 of 14Peng et al. SpringerPlus  (2016) 5:1569 
the SVR24 rate (63.83 vs. 50.00 %) (p = 0.65 > 0.05, Fig. 9). 
Sensitive analysis showed that no individual studies could 
change the pooled results. Publication bias did not exist 
(p = 0.602) when the Begger test was performed.
Safety analysis
Nonspecific adverse events
Four clinical trials (Hézode et al. 2015; Suzuki et al. 2014; 
Izumi et al. 2014; Pol et al. 2012) mentioned nonspecific 
adverse events, which were composed of fatigue, head-
ache, insomnia, nausea, diarrhea, decreased appetite, 
cough, arthralgia, etc. Meta-analysis results indicated 
that there were no significant differences in the non-
specific adverse events between daclatasvir and control 
groups (p > 0.05, Table 3). Sensitive analysis showed that 
no individual studies could change the pooled results. 
Publication bias did not exist (p > 0.05) when the Begger 
test was performed.
Fig. 8 Forest plot of RVR rate of DCV (10 mg/day) + P/R and PBO + P/R for CHC
Fig. 9 Forest plot of SVR rate of DCV (10 mg/day) + P/R and PBO + P/R for CHC
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Liver dysfunction
Four clinical trials (Hézode et al. 2015; Dore et al. 2015; 
Suzuki et al. 2014; Izumi et al. 2014) mentioned the effect 
of daclatasvir on the liver function, which included ele-
vated alanine aminotransferase (ALT), elevated total 
bilirubin (TBil), etc. Meta-analysis results indicated that 
there were no significant differences in the liver dysfunc-
tion between daclatasvir and control groups (p  >  0.05, 
Table  3). Sensitive analysis showed that no individual 
studies could change the pooled results. Publication 
bias did not exist (p  >  0.05) when the Begger test was 
performed.
Hematologic abnormalities
Five clinical trials (Hézode et  al. 2015; Dore et  al. 2015; 
Suzuki et  al. 2014; Izumi et  al. 2014; Pol et  al. 2012) 
mentioned the effect of daclatasvir on the hematologic 
system, which included anemia, thrombocytopenia, 
neutropenia, etc. Meta-analysis results indicated that 
there were no significant differences in the hematologic 
abnormalities between daclatasvir and control groups 
(p > 0.05, Table 3). Sensitive analysis showed that no indi-
vidual studies could change the pooled results. Publica-
tion bias did not exist (p > 0.05) when the Begger test was 
performed.
Skin abnormalities
Five clinical trials (Hézode et  al. 2015; Dore et  al. 2015; 
Suzuki et  al. 2014; Izumi et  al. 2014; Pol et  al. 2012) 
mentioned the effect of daclatasvir on the skin, which 
included rush, pruritus, alopecia, etc. Meta-analysis 
results indicated that there were no significant differences 
in the skin abnormalities between daclatasvir and control 
groups (p > 0.05, Table 3). Sensitive analysis showed that 
no individual studies could change the pooled results. 
Publication bias did not exist (p > 0.05) when the Begger 
test was performed.
Discussion
Hepatitis C virus (HCV) is divided to six genotypes 
and 70 subtypes, of which HCV genotype 1–3 infection 
occupy a leading position, and HCV genotype can influ-
ence disease characteristics, treatment options, and ther-
apeutic response rates (Chinese Society of Hepatology 
et  al. 2015; Ghany et  al. 2009a, b). Due to no immunity 
and repeated infection, CHC is a serious viral infectious 
disease to human health and very difficult to prevent 
(World Health Organization 2016). Before the direct 
antiviral agents (DAA) emerged, the treatment of CHC, 
a regimen of PEG-IFN-α2a or 2b, and ribavirin (RBV) 
remains unsatisfactory, particularly in the large number 
of patients with HCV genotype 1 infection, whose sus-
tained viral response rates are currently 40  % (Ghany 
et al. 2009a, b; European Association for the Study of the 
Liver 2014a, b).
Treatment for HCV infection is rapidly evolving with 
the introduction of direct-acting antiviral (DAA) agents 
(Li 2014; Yang and Wang 2014). The Guidelines Develop-
ment Group recommends that persons with genotype 1 
HCV infection should be considered for treatment with 
Table 3 Detailed adverse events of the included studies
AE adverse event, DCV daclatasvir, P pegylated interferon-α, R ribavirin, PBO placebo
Category Concrete forms Events/total (incidence rate, %) RR (95 % CI) p values
DCV + P/R PBO + P/R
Nonspecific AEs Fatigue 211 (49.76) 62 (58.49) 0.86 (0.72–1.03) 0.11
Headache 184 (43.40) 48 (45.28) 0.96 (0.76–1.21) 0.73
Insomnia 132 (31.13) 36 (33.96) 0.86 (0.64–1.14) 0.29
Nausea 126 (32.31) 29 (29.59) 0.79 (0.37–1.68) 0.53
Diarrhea 90 (23.20) 54 (57.45) 0.52 (0.20–1.36) 0.18
Decreased appetite 104 (24.53) 26 (24.53) 0.99 (0.69–1.44) 0.98
Cough 72 (18.60) 53 (54.08) 0.66 (0.18–2.37) 0.52
Arthralgia 66 (17.01) 24 (25.53) 0.67 (0.44–1.01) 0.06
Liver dysfunction Elevated ALT 9 (1.84) 1 (0.69) 1.51 (0.34–6.68) 0.59
Elevated bilirubin 4 (0.82) 1 (0.69) 0.87 (0.19–4.07) 0.86
Hematologic abnormalities Anemia 45 (8.59) 14 (8.92) 0.92 (0.53–1.59) 0.77
Thrombocytopenia 12 (2.46) 6 (4.14) 0.63 (0.24–1.65) 0.34
Neutropenia 139 (26.53) 46 (29.30) 0.89 (0.67–1.19) 0.44
Skin abnormalities Rash 147 (28.05) 46 (29.30) 0.93 (0.71–1.23) 0.63
Pruritus 179 (34.16) 49 (31.21) 1.06 (0.81–1.38) 0.67
Alopecia 116 (27.36) 23 (21.70) 1.06 (0.50–2.24) 0.88
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the currently approved direct-acting antivirals (telaprevir, 
boceprevir or simeprevir), given in combination with 
PEG-IFN and RBV rather than only PEG-IFN and RBV 
(European Association for the Study of the Liver 2014a, 
b). However, these drugs have to be taken three times 
daily and have a high pill burden, and are associated with 
adverse events, including skin rash and anaemia, which 
might reduce tolerability and adherence (World Health 
Organization 2016).
As far as we know, all-oral, interferon-free combina-
tions of drugs are expected to cure more than 90  % of 
HCV infections and become a hot issue. Even so, a num-
ber of unsolved scientific questions remain. Firstly, IFN-
based regimens are generally cheaper than combinations 
of DAAs without IFN. IFN-based regimens thus could 
be imposed as first line therapies in some settings (Chen 
2016). Secondly, DAAs like sofosbuvir, ledipasvir and 
grazoprevir have not enter developing countries, such as 
China. Thirdly, the results of IFN-based therapies depend 
mainly on the patients’ responsiveness to IFN, which is 
determined genetically, the absence or presence of cir-
rhosis, and the HCV genotype. However, IFN-free regi-
mens are not yet available or efficacious enough in some 
subsets of patients (Jean 2014). Fourthly, viral resistance 
will become an issue for patients who do not respond 
to all-oral, IFN-free regimens. When the drugs are 
approved, erroneous prescriptions, treatment of more 
difficult-to-cure, real-life patients, and/or suboptimal 
adherence to therapy will generate more frequent treat-
ment failures, owing to selection of viruses that are resist-
ant to the different classes of drugs (Jean 2014). Fifthly, if 
patients with decompensated cirrhosis or combined with 
other systemic disease need continuous treatment, DAA 
combinations will increase the risk of drug–drug inter-
action (Chen 2016). In summary, at present, patients in 
developing countries need some acceptable treatment 
options.
Daclatasvir (DCV), a new oral antiviral drug for CHC, 
is a HCV NS5A inhibitor. NS5A is a RNA-binding mul-
tifunctional viral protein and is essential for viral pro-
liferation by interacting with other HCV nonstructural 
proteins and cellular proteins (Keating 2016; Scheel and 
Rice 2013; Qiu et  al. 2011). Studies (Fridell et  al. 2011; 
Lee et  al. 2011; Wang et  al. 2012) have demonstrated 
that DCV exerts antiviral activity by blocking NS3 pro-
tease-mediated cleavage of the viral polyprotein, altering 
the subcellular localisation of NS5A, preventing NS5A 
hyperphosphorylation, and inhibiting the formation of 
viral replication complexes. DCV supports once-daily 
dosing and covers HCV genotype 1–4 infections.
In the present meta-analysis, we included the six high 
quality published RCTs with adult CHC patients (Jadad 
scores  ≥  4) by searching several English and Chinese 
databases and reviewing relevant articles, showing some 
evidence for better therapeutic effect of daclatasvir plus 
the current standard therapeutic regimen (pegIFN-α/
RBV) on CHC, especially HCV genotype 1 infection. 
Daclatasvir-based combination therapy yielded a sig-
nificantly higher probability of achieving the overall 
RVR (46.43 vs. 18.97  %) with pooled RR of 3.77 (95  % 
CI 1.95–7.28, p < 0.0001) and a slightly higher probabil-
ity of achieving the overall SVR24 (65.08 vs. 47.77 %) rate 
with pooled RR of 1.41 (95 % CI 1.18–1.68, p < 0.0001), 
and did not showed increased adverse events compared 
with the current standard therapeutic regimen. Fur-
ther, in the subgroup analysis of high-dose daclatasvir 
(60  mg/day) group, the present meta-analysis showed 
the rate of RVR (49.90 %) with pooled RR of 3.76 (95 % 
CI 1.97–7.16, p < 0.0001) and the rate of SVR24 (68.95 %) 
with pooled RR of 1.44 (95 % CI 1.21–1.71, p < 0.0001) 
were slightly higher than those in the overall analysis. In 
the subgroup analysis of low-dose daclatasvir (10  mg/
day) group, although daclatasvir-based combination 
regimen also indicated a significantly higher probability 
of achieving the RVR (74.47 vs. 7.14 %) with pooled RR 
of 8.79 (95 % CI 2.67–28.95, p < 0.0001), the SVR24 rate 
was similar between the daclatasvir and control groups 
(63.83 vs. 50.00  %) (p  =  0.65). However, the subgroup 
analysis of low-dose daclatasvir (10 mg/day) group only 
included the three studies, and obviously the reliability of 
the results was poorer than high-dose daclatasvir (60 mg/
day) group (including the six studies). The above results 
suggest that daclatasvir is a powerful and direct antiviral 
agents with improved RVR and SVR rates, oral route of 
delivery, once-daily administration, and less side effects. 
Therefore, it is recommended that daclatasvir, pegIFN 
and RBV triple therapy could be used as a treatment of 
CHC, especially HCV genotype 1 infection. As far as we 
know, this was the first meta-analysis that revealed that 
daclatasvir in combination with peg-IFN-α/RBV could 
achieve satisfactory therapeutic effects.
There were limitations to our meta-analysis that should 
be considered. The main limitation of this study was a 
small number of included RCTs and patients (six RCTs 
and 1100 patients). Secondly, the course of treatment 
were not consistent among the six RCTs with large span 
(12–48 weeks). Thirdly, daclatasvir emerged late, and the 
observation time of the included RCTs was 24 weeks with 
a lack of longer follow-up information, so the long-term 
efficacy was unclear. Fourthly, HCV genotype 1 infec-
tion accounted for 73.1 %, genotype 2–3 infection 22.2 %, 
and genotype 4 infection 4.7 % in the included 1100 adult 
patients. Due to the limited number of cases, we couldn’t 
provide subgroup analysis data on the basis of the four 
genotypes. Lastly, the limitation of possible publication 
bias should be taken into consideration because the study 
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with positive results were easier to be reported, although 
possibility of publication bias did not existed using the 
Begger test.
In summary, this meta-analysis indicated that high-
dose daclatasvir (60  mg/day) in combination with peg-
IFN-α/RBV is effective and safe in treating adult patients 
with CHC, especially HCV genotype 1 infection. We 
believe daclatasvir in combination with peg-IFN-α/RBV 
could be respected as a natural bridge between the past 
(peg-IFN and ribavirin) and the current (IFN free direct 
antiviral agents), which has guiding significance to clini-
cal work. To obtain an exact finding with respect to 
daclatasvir use of CHC treatment, additional high-qual-
ity, large sample and multicenter, randomized, double-
blind, placebo-controlled clinical trials on this issue are 
needed.
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